BR112022020609A2 - Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo - Google Patents

Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo

Info

Publication number
BR112022020609A2
BR112022020609A2 BR112022020609A BR112022020609A BR112022020609A2 BR 112022020609 A2 BR112022020609 A2 BR 112022020609A2 BR 112022020609 A BR112022020609 A BR 112022020609A BR 112022020609 A BR112022020609 A BR 112022020609A BR 112022020609 A2 BR112022020609 A2 BR 112022020609A2
Authority
BR
Brazil
Prior art keywords
solvate
hydrate
pharmaceutically acceptable
acceptable salt
oral administration
Prior art date
Application number
BR112022020609A
Other languages
English (en)
Inventor
Maximilien Jacqueline
Rajan Gopal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112022020609A2 publication Critical patent/BR112022020609A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA PARA ADMINISTRAÇÃO ORAL QUE COMPREENDE DERIVADO DE AMINOPIRIMIDINA OU SAL, HIDRATO OU SOLVATO FARMACEUTICAMENTE ACEITÁVEL DO MESMO. A presente revelação fornece composições farmacêuticas para administração oral que compreende N-(5-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidina-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida ou o sal, hidrato ou solvato farmaceuticamente aceitável do mesmo como um ingrediente ativo; e uma combinação de (i) um derivado de celulose e (ii) um açúcar ou poliol como diluentes. As composições reveladas são caracterizadas por capacidade de fabricação aprimorada, enquanto mantêm os benefícios farmacêuticos de minimizar o efeito de acordo com as alterações no ambiente de pH no estômago, tendo excelente estabilidade e exibindo boa biodisponibilidade.
BR112022020609A 2020-04-14 2021-04-13 Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo BR112022020609A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009623P 2020-04-14 2020-04-14
US202063014277P 2020-04-23 2020-04-23
PCT/IB2021/053035 WO2021209893A1 (en) 2020-04-14 2021-04-13 Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof

Publications (1)

Publication Number Publication Date
BR112022020609A2 true BR112022020609A2 (pt) 2022-11-29

Family

ID=75562794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020609A BR112022020609A2 (pt) 2020-04-14 2021-04-13 Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo

Country Status (13)

Country Link
US (1) US20210322323A1 (pt)
EP (1) EP4135669A1 (pt)
JP (1) JP2023522634A (pt)
KR (1) KR20230002656A (pt)
CN (1) CN115484937A (pt)
AU (1) AU2021257662A1 (pt)
BR (1) BR112022020609A2 (pt)
CA (1) CA3180184A1 (pt)
IL (1) IL297240A (pt)
MX (1) MX2022012898A (pt)
TW (1) TW202207940A (pt)
UY (1) UY39171A (pt)
WO (1) WO2021209893A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
EP4349835A1 (en) * 2021-06-01 2024-04-10 Hangzhou Solipharma Co., Ltd. Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
WO2023138492A1 (zh) * 2022-01-19 2023-07-27 南京明德新药研发有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437006B1 (en) * 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
EP2076250B1 (en) * 2006-10-27 2011-01-05 FMC Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
HUE052548T2 (hu) 2012-11-21 2021-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
WO2015006753A2 (en) * 2013-07-12 2015-01-15 The Regents Of The University Of California Therapies for diseases caused by arthropod-borne parasites
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
HUE054848T2 (hu) 2014-10-13 2021-09-28 Yuhan Corp Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
RU2745195C2 (ru) * 2016-04-07 2021-03-22 Кемосентрикс, Инк. Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
MA47310A (fr) * 2017-01-20 2019-11-27 Exelixis Inc Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2021209893A8 (en) 2022-10-13
JP2023522634A (ja) 2023-05-31
WO2021209893A1 (en) 2021-10-21
US20210322323A1 (en) 2021-10-21
UY39171A (es) 2021-10-29
KR20230002656A (ko) 2023-01-05
AU2021257662A1 (en) 2022-12-15
TW202207940A (zh) 2022-03-01
CN115484937A (zh) 2022-12-16
CA3180184A1 (en) 2021-10-21
EP4135669A1 (en) 2023-02-22
IL297240A (en) 2022-12-01
MX2022012898A (es) 2023-01-24

Similar Documents

Publication Publication Date Title
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
CY1114118T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
BR112012010124A2 (pt) composto, uso de um animal composto, derivado de cromenona, e, método para o tratamento ou prevenção de um animal de sangue quente tendo tumores que são sensíveis á inibição das enzimas de pi 3-cinase
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
SE0402735D0 (sv) Novel compounds
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
BRPI0517891A (pt) composições compreendendo azelastina e métodos de uso das mesmas
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201190012A1 (ru) Твердые лекарственные формы бендамустина
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
BR112020007589A8 (pt) Derivados de benzimidazol e seus usos
BRPI0514724A (pt) inibidores da enzima hiv integrase
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon
AU2008203743A1 (en) Thioxanthene derivates useful to treat infectious diseases
EA200970570A1 (ru) Макролидные соединения, обладающие противовоспалительной активностью
BRPI0418770A (pt) combinação antimicobacteriana, composição farmacêutica antimicobacteriana e processo para a preparação de uma composição farmacêutica antimicobacteriana